GWM
IMVT icon

Geneos Wealth Management’s Immunovant IMVT Stock Holding History

Geneos Wealth Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.5K Hold
1,000
– – ﹤0.01% 1563
2026
Q1 		$24.8K Hold
1,000
– – ﹤0.01% 1694
2025
Q4 		$25.4K Buy
+1,000
New +$22.3K ﹤0.01% 1647

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geneos Wealth Management's IMVT Position: Q2 2026 in Review

Geneos Wealth Management held its Immunovant (IMVT) position steady in Q2 2026 at 1,000 shares worth $38.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1563.

Geneos Wealth Management first reported a position in IMVT in Q4 2025 and has held it in 3 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Geneos Wealth Management held 1,000 shares of Immunovant worth $38.5K as of Q2 2026.
  • Geneos Wealth Management left its Immunovant share count unchanged in Q2 2026.
  • Immunovant made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1563 holding.
  • Geneos Wealth Management first reported a position in Immunovant in Q4 2025 and has held it in 3 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.